NOMA vs ABCL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABCL Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Momentum & Technical, Options & Structure while NOMA counters with relative strength in Growth & Margin. Fundamentally, NOMA trades at N/M Forward P/E with -164.5% operating margin (+122.9% YoY revenue) versus ABCL at 27.6x Forward P/E and -298.0% operating margin (+18.8% YoY). In options structure, NOMA sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ABCL sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NOMA | ABCL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $22.3M | $3.6B | Larger Scale | ABCL |
| Trailing P/E Ratio Valuation | N/M | 27.6x | Lower Multiple | ABCL |
| Forward P/E Ratio Valuation | N/M | 27.6x | Lower Multiple | ABCL |
| Revenue Growth (YoY) Growth | +122.9% | +18.8% | Higher Growth | NOMA |
| Operating Margin (TTM) Profitability | -164.5% | -298.0% | Higher Margin | NOMA |
| Net Profit Margin Profitability | -213.9% | -218.6% | Higher Margin | NOMA |
| Return on Equity (ROE) Capital Efficiency | -40.7% | -14.6% | Higher ROE | ABCL |
| 52-Week Range Position Momentum | 3% ($1โ$10) | 63% ($3โ$15) | Stronger Trend | ABCL |
| Beta / 30D Volatility Risk Regime | -0.45ฮฒ ยท 156% Vol | 2.30ฮฒ ยท 85% Vol | Lower Realized Risk | ABCL |
| Unified Institutional Score Composite Signal | 49.5 / 100 (HOLD) | 58.6 / 100 (HOLD) | Higher Composite | ABCL |